Is there a potential for therapeutic drug monitoring of subcutaneously administered tocilizumab in patients with rheumatoid arthritis in daily practice?

Z. Layegh; F. Hooijberg; C. Bastida; A. D.R. Huitema; T. Rispens; C. G. Wolbink

doi:10.55563/CLINEXPRHEUMATOL/XN5I2Y

Is there a potential for therapeutic drug monitoring of subcutaneously administered tocilizumab in patients with rheumatoid arthritis in daily practice?

Z. Layegh
, F. Hooijberg
, C. Bastida
, A. D.R. Huitema
, T. Rispens
, C. G. Wolbink

Research output: Contribution to journal › Letter › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	664-665
Number of pages	2
Journal	Clinical and experimental rheumatology
Volume	40
Issue number	3
DOIs	https://doi.org/10.55563/CLINEXPRHEUMATOL/XN5I2Y
Publication status	Published - 2022
Externally published	Yes

Access to Document

10.55563/CLINEXPRHEUMATOL/XN5I2Y

Cite this

@article{1eeb16de425d4c64aa25b0a83c9468b8,

title = "Is there a potential for therapeutic drug monitoring of subcutaneously administered tocilizumab in patients with rheumatoid arthritis in daily practice?",

author = "Z. Layegh and F. Hooijberg and C. Bastida and Huitema, \{A. D.R.\} and T. Rispens and Wolbink, \{C. G.\}",

year = "2022",

doi = "10.55563/CLINEXPRHEUMATOL/XN5I2Y",

language = "English",

volume = "40",

pages = "664--665",

journal = "Clinical and experimental rheumatology",

issn = "0392-856X",